PRDM16 Isoforms Differentially Regulate Normal and Leukemic Hematopoiesis and Inflammatory Gene Signature

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2018 Jun 8

PMID 29878897

Citations 25

Authors

David J Corrigan

Larry L Luchsinger

Mariana Justino de Almeida

Linda J Williams

Alexandros Strikoudis

Hans-Willem Snoeck

Affiliations

Soon will be listed here.

Abstract

PRDM16 is a transcriptional coregulator involved in translocations in acute myeloblastic leukemia (AML), myelodysplastic syndromes, and T acute lymphoblastic leukemia that is highly expressed in and required for the maintenance of hematopoietic stem cells (HSCs), and can be aberrantly expressed in AML. Prdm16 is expressed as full-length (fPrdm16) and short (sPrdm16) isoforms, the latter lacking the N-terminal PR domain. The role of both isoforms in normal and malignant hematopoiesis is unclear. We show here that fPrdm16 was critical for HSC maintenance, induced multiple genes involved in GTPase signaling, and repressed inflammation, while sPrdm16 supported B cell development biased toward marginal zone B cells and induced an inflammatory signature. In a mouse model of human MLL-AF9 leukemia, fPrdm16 extended latency, while sPrdm16 shortened latency and induced a strong inflammatory signature, including several cytokines and chemokines that are associated with myelodysplasia and with a worse prognosis in human AML. Finally, in human NPM1-mutant and in MLL-translocated AML, high expression of PRDM16, which negatively impacts outcome, was associated with inflammatory gene expression, thus corroborating the mouse data. Our observations demonstrate distinct roles for Prdm16 isoforms in normal HSCs and AML, and identify sPrdm16 as one of the drivers of prognostically adverse inflammation in leukemia.

Citing Articles

Clinical value of serum PRDM16 in early diagnosis and prognosis assessment of lung adenocarcinoma.

Fan M, Li M, Zhou J, Li A, Sun Y, Shi P Mol Biol Rep. 2025; 52(1):225.

PMID: 39937385 DOI: 10.1007/s11033-025-10315-7.

Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches.

Li X, Xu F, Zhang P, Mao L, Guo Y, Li H MedComm (2020). 2024; 5(10):e737.

PMID: 39309696 PMC: 11416085. DOI: 10.1002/mco2.737.

A PRDM16-driven signal regulates body composition in testosterone-treated hypogonadal men.

Bathina S, Colleluori G, Villareal D, Aguirre L, Chen R, Armamento-Villareal R Front Endocrinol (Lausanne). 2024; 15:1426175.

PMID: 39286266 PMC: 11402695. DOI: 10.3389/fendo.2024.1426175.

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.

Barreyro L, Sampson A, Hueneman K, Choi K, Christie S, Ramesh V iScience. 2024; 27(6):109809.

PMID: 38784013 PMC: 11112336. DOI: 10.1016/j.isci.2024.109809.

Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.

Guru Murthy G, Zhang T, Bolon Y, Spellman S, Dong J, Auer P Biomark Res. 2024; 12(1):10.

PMID: 38273355 PMC: 10809608. DOI: 10.1186/s40364-023-00550-0.

References

Ho T, Warr M, Adelman E, Lansinger O, Flach J, Verovskaya E . Autophagy maintains the metabolism and function of young and old stem cells. Nature. 2017; 543(7644):205-210. PMC: 5344718. DOI: 10.1038/nature21388. View

Patnaik M, Timm M, Vallapureddy R, Lasho T, Ketterling R, Gangat N . Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017; 7(7):e584. PMC: 5549258. DOI: 10.1038/bcj.2017.66. View

Wang J, Deretic D . The Arf and Rab11 effector FIP3 acts synergistically with ASAP1 to direct Rabin8 in ciliary receptor targeting. J Cell Sci. 2015; 128(7):1375-85. PMC: 4379727. DOI: 10.1242/jcs.162925. View

Sakai I, Tamura T, Narumi H, Uchida N, Yakushijin Y, Hato T . Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer. 2005; 44(3):265-70. DOI: 10.1002/gcc.20241. View

Nayak R, Chang K, Vaitinadin N, Cancelas J . Rho GTPases control specific cytoskeleton-dependent functions of hematopoietic stem cells. Immunol Rev. 2013; 256(1):255-68. PMC: 3830525. DOI: 10.1111/imr.12119. View

Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M . Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood. 2003; 103(7):2753-60. DOI: 10.1182/blood-2003-07-2482. View

Kornblau S, McCue D, Singh N, Chen W, Estrov Z, Coombes K . Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010; 116(20):4251-61. PMC: 4081283. DOI: 10.1182/blood-2010-01-262071. View

Mochizuki N, Shimizu S, Nagasawa T, Tanaka H, Taniwaki M, Yokota J . A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 2000; 96(9):3209-14. View

Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula S . Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2):311-7. PMC: 2118216. DOI: 10.1084/jem.20052204. View

10.

Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H . High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia. 2015; 29(5):1076-83. DOI: 10.1038/leu.2015.5. View

11.

Florian M, Dorr K, Niebel A, Daria D, Schrezenmeier H, Rojewski M . Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 2012; 10(5):520-30. PMC: 3348626. DOI: 10.1016/j.stem.2012.04.007. View

12.

Eveillard M, Delaunay J, Richebourg S, Lode L, Garand R, Wuilleme S . The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica. 2015; 100(3):e114-5. PMC: 4349292. DOI: 10.3324/haematol.2014.121079. View

13.

Liu F, van der Lijn F, Schurmann C, Zhu G, Chakravarty M, Hysi P . A genome-wide association study identifies five loci influencing facial morphology in Europeans. PLoS Genet. 2012; 8(9):e1002932. PMC: 3441666. DOI: 10.1371/journal.pgen.1002932. View

14.

Kim J, Sohn S, Kim D, Baek J, Lee N, Suh J . Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005; 46(6):885-91. DOI: 10.1080/10428190500054491. View

15.

Suzuki-Utsunomiya K, Hadano S, Otomo A, Kunita R, Mizumura H, Osuga H . ALS2CL, a novel ALS2-interactor, modulates ALS2-mediated endosome dynamics. Biochem Biophys Res Commun. 2007; 354(2):491-7. DOI: 10.1016/j.bbrc.2006.12.229. View

16.

Aguilo F, Avagyan S, Labar A, Sevilla A, Lee D, Kumar P . Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood. 2011; 117(19):5057-66. PMC: 3109532. DOI: 10.1182/blood-2010-08-300145. View

17.

Aguayo A, Kantarjian H, Estey E, Giles F, Verstovsek S, Manshouri T . Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002; 95(9):1923-30. DOI: 10.1002/cncr.10900. View

18.

Xiao Z, Zhang M, Liu X, Zhang Y, Yang L, Hao Y . MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leuk Res. 2005; 30(3):332-4. DOI: 10.1016/j.leukres.2005.07.002. View

19.

Halvarsson C, Eliasson P, Jonsson J . Pyruvate dehydrogenase kinase 1 is essential for transplantable mouse bone marrow hematopoietic stem cell and progenitor function. PLoS One. 2017; 12(2):e0171714. PMC: 5300157. DOI: 10.1371/journal.pone.0171714. View

20.

Mzoughi S, Tan Y, Low D, Guccione E . The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev. 2016; 36:83-91. DOI: 10.1016/j.gde.2016.03.009. View